Principal Bioinformatician - Experimental Cancer Genetics
||Wellcome Sanger Institute
||£43,722 - £52,903
||The Wellcome Trust Sanger Institute
Salary in the region of £43,722- £52,903 dependent on experience) plus excellent benefits
Fixed term for 5 years
The Experimental Cancer Genetics group aims to identify cancer genes and to understand their function (https://www.sanger.ac.uk/research/faculty/dadams/). We are also interested in how genes interact to promote cancer development, and how these interactions may be exploited for therapy. Examples of recent studies include the identification of genes associated with familial melanoma (1), pan-drivers of cancer development (2), and genes that regulate genomic stability (3). The group is a mixture of pure wetlab, mixed wet/dry lab students and postdocs; with computational support provided by two Senior Bioinformaticians.
We are now seeking to recruit a Principal Bioinformatician who can facilitate the scientific work of the group by leading the computational data analysis support for the team and their collaborators. Many of our experiments involve the generation of large quantities of either whole-genome or exome sequencing data which require strong computational skills to 1) create high quality mutation calls 2) carry out statistical analysis to interpret the functional consequences 3) evaluate newly published tools to identify new types of mutations or signatures of mutation. Integrating genomic data with other data forms is also another important part of what we do. The group also performs CRISPR screens and uses the last analysis tools to explore these data.
The post-holder must be a good communicator and be able to understand the scientific background and technical detail of the team's projects, and be to be proficient at devising and implementing software solutions and statistical analysis. The role would also involve line management and day to day supervision for bioinformaticians in the team.
(1) Wong et al. (2018) Cross-species genomic comparison of human mucosal, canine oral and equine melanoma. Nature Communications - in press.
(3) van der Weyden et al., (2017) Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. Nature, 12:233-236
(3). Robles et al., (2014) POT1 loss-of-function variants predispose to familial melanoma. Nature Genetics, 46:478-481
Genome Research Limited is an Equal Opportunity employer. As part of our commitment to equality, diversity and inclusion and promoting equality in careers in science, we hold an Athena SWAN Bronze Award and have an active Equality, Diversity and Inclusion programme of activity. We will consider all applicants without discrimination on grounds of disability, sexual orientation, pregnancy or maternity leave status, race or national or ethnic origin, age, religion or belief, gender identity or re-assignment, marital or civil partnership status, protected veteran status (if applicable) or any other characteristic protected by law. We are open to a range of UK-based flexible working options including part-time or full-time employment as well as flexible hours due to caring or other commitments.
Please include a covering letter and CV with your application.
Closing date: 19th December 2018. Applications will be considered and reviewed on an on-going basis. We aim to hold face to face interviews in January 2019.